e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Kymera Therapeutics, Inc. - Common Stock (NQ:KYMR)

79.48 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Kymera Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Mid-Day Market Update: Dow Jumps 100 Points; Spero Therapeutics Shares Plunge ↗

May 03, 2022

U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 100 points on Tuesday.

Via Benzinga

41 Stocks Moving In Tuesday's Mid-Day Session ↗

May 03, 2022

Gainers SoundHound AI, Inc. (NASDAQ: SOUN) shares jumped 47.4% to $16.13. The company recently completed a SPAC merger deal last week and began trading on Thursday. Sonoma...

Via Benzinga

Kymera Therapeutics: Q1 Earnings Insights ↗

May 03, 2022

Kymera Therapeutics (NASDAQ:KYMR) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Analyst Ratings for Kymera Therapeutics ↗

April 28, 2022

Kymera Therapeutics (NASDAQ:KYMR) has observed the following analyst ratings within the last quarter:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022 ↗

April 28, 2022

Via Benzinga

Kymera Therapeutics Q1 2022 Earnings Conference Call On May 3, 2022 At 08:00 AM ET ↗

April 21, 2022

Kymera Therapeutics (NASDAQ:KYMR) will host a conference call at 08:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results. How to Attend Kymera Therapeutics (KYMR) Conference Call Follow this...

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

March 18, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

JPMorgan Sees 'Limited Upside Potential' In Kymera Therapeutics' KT-474 ↗

March 10, 2022

JPMorgan has initiated the coverage of Kymera Therapeutics Inc (NASDAQ: KYMR) with a Neutral rating and a $44 price target. Analyst Eric Joseph says...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2022 ↗

March 10, 2022

Upgrades For Alpha Metallurgical Resources Inc (NYSE:AMR), B. Riley Securities upgraded the previous rating of Neutral to Buy. For the fourth quarter, Alpha Metallurgical...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2022 ↗

February 10, 2022

Upgrades According to Gordon Haskett, the prior rating for Williams-Sonoma Inc (NYSE:WSM) was changed from Hold to Accumulate. Williams-Sonoma earned $3.32 in the third quarter,...

Via Benzinga

48 Biggest Movers From Yesterday ↗

January 14, 2022

Gainers Singularity Future Technology Ltd. (NASDAQ: SGLY) shares rose 25.9% to settle at $5.01 on Thursday. MedAvail Holdings, Inc (NASDAQ: MDVL) gained 24.4% to settle at $1.58...

Via Benzinga

Kymera Discloses New Development Cancer Program ↗

December 16, 2021

Kymera Therapeutics Inc (NASDAQ: KYMR) has added KT-253 to its pipeline, targeted at liquid and solid tumors. KT-253, a selective degrader of MDM2, has the potential to...

Via Benzinga

The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street ↗

December 16, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug...

Via Benzinga

Where Kymera Therapeutics Stands With Analysts ↗

September 30, 2021

Over the past 3 months, 5 analysts have published their opinion on Kymera Therapeutics (NASDAQ:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021 ↗

September 30, 2021

Upgrades For Cabot Oil & Gas Corp (NYSE:COG),...

Via Benzinga

The Past Week's Notable Insider Buys Include Krispy Kreme, Biotechs, SPACs And More ↗

July 11, 2021

Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Initial and secondary public offerings enticed insiders to...

Via Benzinga

The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold ↗

September 17, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Bicycle Therapeutics plc (...

Via Benzinga

Kymera Prices $223M Equity Offering At $47/Share ↗

July 01, 2021

Kymera Therapeutics Inc (NASDAQ: KYMR) has priced its upsized underwritten public offering of 4.7 million shares at $47.00 per share, representing a discount...

Via Benzinga

58 Biggest Movers From Yesterday ↗

July 02, 2021

Gainers The Glimpse Group, Inc. (NASDAQ: VRAR) shares jumped 152.3% to settle at $17.66 on Thursday after the company priced its IPO at $7 per share. Pop Culture Group Co., Ltd (...

Via Benzinga

Topics Initial Public Offering

31 Stocks Moving in Wednesday's Pre-Market Session ↗

June 30, 2021

Gainers Bridgeline Digital, Inc. (NASDAQ: BLIN) shares rose 83% to $6.20 in pre-market trading. Bridgeline Digital shares jumped over 36% on Tuesday on above-average volume....

Via Benzinga

72 Biggest Movers From Yesterday ↗

July 01, 2021

Gainers Pop Culture Group Co., Ltd (NASDAQ: CPOP) shares jumped 405% to close at $30.30 on Wednesday after the company priced its IPO at $6 per share. Cuentas Inc. (NASDAQ: CUEN...

Via Benzinga

Topics Initial Public Offering

Kymera Therapeutics Seeks To Raise Capital Via 4M Shares Equity Offering To Fund Oncology Franchises ↗

June 29, 2021

Kymera Therapeutics Inc (NASDAQ: KYMR) commenced an underwritten public offering of 4 million shares of common stock. Underwriters can purchase up to an...

Via Benzinga

51 Stocks Moving In Wednesday's Mid-Day Session ↗

June 30, 2021

Gainers Cuentas Inc. (NASDAQ: CUEN) shares jumped 176.6% to $7.69. The stock spiked following a press release saying "WaveMax to Implement the World's First Shared Wifi6...

Via Benzinga

44 Stocks Moving In Monday's Mid-Day Session ↗

June 28, 2021

Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy. Marin Software...

Via Benzinga

60 Biggest Movers From Yesterday ↗

June 29, 2021

Gainers Marin Software Incorporated (NASDAQ: MRIN) surged 96.9% to close at $7.50. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its...

Via Benzinga

Kymera's KT-474 Achieved Sustained IRAK4 Reduction After Single Dose In Healthy Volunteers ↗

June 28, 2021

Kymera Therapeutics Inc (NASDAQ: KYMR) has announced interim results from the Single Ascending Dose (SAD) portion of the Phase 1 trial of KT-474 in healthy...

Via Benzinga

Kymera Therapeutics' KT-413 Shows Encouraging Preclinical Anti-Cancer Activity ↗

June 21, 2021

Kymera Therapeutics Inc (NASDAQ: KYMR) has announced new preclinical data on its IRAKIMiD degrader KT-413's potential as both a monotherapy and in combination...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 21, 2021 ↗

May 21, 2021

Upgrades According to JP Morgan, the prior rating for ResMed Inc (NYSE:RMD) was changed from Neutral to Overweight. For the third quarter, ResMed had an EPS of $1.30,...

Via Benzinga

The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data ↗

May 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

48 Biggest Movers From Yesterday ↗

April 15, 2021

Gainers Alkami Technology, Inc. (NASDAQ: ALKT) shares surged 43.3% to settle at $43.00 on Wednesday after the company priced its IPO at $30 per share. Coinbase Global, Inc. (...

Via Benzinga

Topics Initial Public Offering

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy